Zobrazeno 1 - 10
of 488
pro vyhledávání: '"Carlos, Camps"'
KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination
Autor:
Rafael Rosell, Eloisa Jantus-Lewintre, Peng Cao, Xueting Cai, Baojuan Xing, Masaoki Ito, Jose Luis Gomez-Vazquez, Mireia Marco-Jordán, Silvia Calabuig-Fariñas, Andrés Felipe Cardona, Jordi Codony-Servat, Jessica Gonzalez, Kevin València-Clua, Andrés Aguilar, Carlos Pedraz-Valdunciel, Zahra Dantes, Anisha Jain, S Chandan, Miguel Angel Molina-Vila, Oscar Arrieta, Macarena Ferrero, Carlos Camps, Maria González-Cao
Publikováno v:
Cell Communication and Signaling, Vol 22, Iss 1, Pp 1-15 (2024)
Abstract Background KRAS-mutant non-small cell lung cancer (NSCLC) shows a relatively low response rate to chemotherapy, immunotherapy and KRAS-G12C selective inhibitors, leading to short median progression-free survival, and overall survival. The ME
Externí odkaz:
https://doaj.org/article/6654162f004044148f38c519b8f50a91
Autor:
Susana Torres‐Martínez, Silvia Calabuig‐Fariñas, Andrea Moreno‐Manuel, Giulia Bertolini, Alejandro Herreros‐Pomares, Eva Escorihuela, Elena Duréndez‐Saéz, Ricardo Guijarro, Ana Blasco, Luca Roz, Carlos Camps, Eloisa Jantus‐Lewintre
Publikováno v:
Molecular Oncology, Vol 18, Iss 1, Pp 190-215 (2024)
Despite the success of therapies in lung cancer, more studies of new biomarkers for patient selection are urgently needed. The present study aims to analyze the role of galectin‐3 (GAL‐3) in the lung tumor microenvironment (TME) using tumorsphere
Externí odkaz:
https://doaj.org/article/e94f49441c4e4aeda21fd85df71bca0e
Autor:
Ana Patiño-García, Elizabeth Guruceaga, Maria Pilar Andueza, Marimar Ocón, Jafait Junior Fodop Sokoudjou, Nicolás de Villalonga Zornoza, Gorka Alkorta-Aranburu, Ibon Tamayo Uria, Alfonso Gurpide, Carlos Camps, Eloísa Jantus-Lewintre, Maria Navamuel-Andueza, Miguel F. Sanmamed, Ignacio Melero, Mohamed Elgendy, Juan Pablo Fusco, Javier J. Zulueta, Juan P. de-Torres, Gorka Bastarrika, Luis Seijo, Ruben Pio, Luis M. Montuenga, Mikel Hernáez, Idoia Ochoa, Jose Luis Perez-Gracia
Publikováno v:
EBioMedicine, Vol 102, Iss , Pp 105048- (2024)
Summary: Background: Tobacco is the main risk factor for developing lung cancer. Yet, while some heavy smokers develop lung cancer at a young age, other heavy smokers never develop it, even at an advanced age, suggesting a remarkable variability in t
Externí odkaz:
https://doaj.org/article/325b5d8d436b42f0be4be23054440e34
Autor:
Cristina Candal-Pedreira, Alberto Ruano-Ravina, Virginia Calvo de Juan, Manuel Cobo, José Manuel Trigo, Enric Carcereny, Marc Cucurull, Rafael López Castro, Eduardo Solís García, Amparo Sánchez-Gastaldo, Bartomeu Massutí, Delvys Rodríguez-Abreu, Anna Estival, María Guirado Risueño, María Pamiés Ramón, Rosario García Campelo, Guillermo Alonso-Jáudenes, Carlos Camps, Edel del Barco Morillo, Clara González Ojea, Manuel Dómine, Alfredo Sanchez-Hernandez, Joaquím Bosch-Barrera, María Ángeles Sala González, Mariano Provencio
Publikováno v:
ERJ Open Research, Vol 9, Iss 6 (2023)
Objectives The aim of the study was to ascertain the percentage of Spanish lung cancer cases that would fulfil the lung cancer screening inclusion criteria recommended by the United States Preventive Service Task Force (USPSTF) in 2013 and 2021. Meth
Externí odkaz:
https://doaj.org/article/a612acb88ba047f79e4cc339b0b86a9c
Autor:
Meri-Abad, Marina, Moreno-Manuel, Andrea, García, Sandra Gallach, Calabuig-Fariñas, Silvia, Pérez, Rafael Sirera, Herrero, Carlos Camps, Jantus-Lewintre, Eloisa
Publikováno v:
In Critical Reviews in Oncology / Hematology February 2023 182
Autor:
Susana Torres-Martínez, Silvia Calabuig-Fariñas, Sandra Gallach, Marais Mosqueda, Ester Munera-Maravilla, Rafael Sirera, Lara Navarro, Ana Blasco, Carlos Camps, Eloisa Jantus-Lewintre
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 24, p 17587 (2023)
Immunotherapy has been proven a viable treatment option for non-small cell lung cancer (NSCLC) treatment in patients. However, some patients still do not benefit. Finding new predictive biomarkers for immunocheckpoint inhibitor (ICI) response will im
Externí odkaz:
https://doaj.org/article/4dff53ea28344440a8c674c8c3cb60c4
Autor:
Mariano Provencio, Manuel Cobo, Delvys Rodriguez-Abreu, Virginia Calvo, Enric Carcereny, Alexandra Cantero, Reyes Bernabé, Gretel Benitez, Rafael López Castro, Bartomeu Massutí, Edel del Barco, Rosario García Campelo, Maria Guirado, Carlos Camps, Ana Laura Ortega, Jose Luis González Larriba, Alfredo Sánchez, Joaquín Casal, M. Angeles Sala, Oscar Juan-Vidal, Joaquim Bosch-Barrera, Juana Oramas, Manuel Dómine, Jose Manuel Trigo, Remei Blanco, Julia Calzas, Idoia Morilla, Airam Padilla, Joao Pimentao, Pedro A. Sousa, Maria Torrente
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background The survival of patients with lung cancer has substantially increased in the last decade by about 15%. This increase is, basically, due to targeted therapies available for advanced stages and the emergence of immunotherapy itself.
Externí odkaz:
https://doaj.org/article/0111fe9f31fa49208eab155d42059c73
Autor:
Estela Sánchez‐Herrero, Roberto Serna‐Blasco, Vadym Ivanchuk, Rosario García‐Campelo, Manuel Dómine Gómez, José M. Sánchez, Bartomeu Massutí, Noemi Reguart, Carlos Camps, Sandra Sanz‐Moreno, Silvia Calabuig‐Fariñas, Eloísa Jantus‐Lewintre, Magdalena Arnal, Dietmar Fernández‐Orth, Virginia Calvo, Víctor González‐Rumayor, Mariano Provencio, Atocha Romero
Publikováno v:
Molecular Oncology, Vol 15, Iss 9, Pp 2363-2376 (2021)
Despite impressive and durable responses, nonsmall cell lung cancer (NSCLC) patients treated with anaplastic lymphoma kinase (ALK) inhibitors (ALK‐Is) ultimately progress due to development of resistance. Here, we have evaluated the clinical utilit
Externí odkaz:
https://doaj.org/article/f8857d8e937348c0ac60929a958c48fe
Autor:
Pilar Garrido, Luis Paz‐Ares, Margarita Majem, Teresa Morán, José Manuel Trigo, Joaquim Bosch‐Barrera, Rosario Garcίa‐Campelo, José Luis González‐Larriba, José Miguel Sánchez‐Torres, Dolores Isla, Núria Viñolas, Carlos Camps, Amelia Insa, Óscar Juan, Bartomeu Massuti, Alfredo Paredes, Ángel Artal, Marta López‐Brea, José Palacios, Enriqueta Felip
Publikováno v:
Cancer Medicine, Vol 10, Iss 17, Pp 5878-5888 (2021)
Abstract Objectives The aim of LungBEAM was to determine the value of a novel epidermal growth factor receptor (EGFR) mutation test in blood based on BEAMing technology to predict disease progression in advanced non‐small cell lung cancer (NSCLC) p
Externí odkaz:
https://doaj.org/article/2cc59ca7f06b4dfda7263238d2a0d956
Autor:
Lourdes Gutiérrez, Ana Royuela, Enric Carcereny, Rafael López-Castro, Delvys Rodríguez-Abreu, Bartomeu Massuti, José Luis González-Larriba, Rosario García-Campelo, Joaquim Bosch-Barrera, María Guirado, Carlos Camps, Manuel Dómine, Reyes Bernabé, Joaquín Casal, Juana Oramas, Ana Laura Ortega, Mª. Angeles Sala, Airam Padilla, David Aguiar, Oscar Juan-Vidal, Remei Blanco, Edel del Barco, Natividad Martínez-Banaclocha, Gretel Benítez, Blanca de Vega, Ainhoa Hernández, Maria Saigi, Fernando Franco, Mariano Provencio
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background There is a lack of useful diagnostic tools to identify EGFR mutated NSCLC patients with long-term survival. This study develops a prognostic model using real world data to assist clinicians to predict survival beyond 24 months. Me
Externí odkaz:
https://doaj.org/article/233d05bfad794aa8b762c296fe046b5c